Pharmacy Management Drug Policy

SUBJECT: Chronic Hepatitis C (Pegasys, Peg-Intron, ribavirin, Olysio, Sovaldi, Harvoni, ledipasvir/sofosbuvir, Viekira, Viekira XR, Daklinza, Technivie, Zepatier, Epclusa, sofosbuvir/velpatasvir, Vosevi, Mavyret) for Commercial, NYSOH Individual Market, and NYSOH Employer Group Market Products
POLICY NUMBER: Pharmacy-21
EFFECTIVE DATE: 6/03
LAST REVIEW DATE: 6/3/2019

If the member’s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered under that contract. In such cases, medical or drug policy criteria are not applied. Medical or drug policies apply to commercial and Health Care Reform products only when a contract benefit for the specific service exists.

DESCRIPTION:

Chronic infection with hepatitis C virus (HCV) is the most common cause of cirrhosis and hepatocellular carcinoma and the most frequent indication for liver transplant in the United States.

Certain terms have been defined in multiple ways in different studies and treatment guidelines. Below is a list of terms and their meanings for the purposes of this policy:

Rapid virologic response (RVR) - undetectable HCV at week 4
Sustained virologic response (SVR) - undetectable HCV at time of test (12, 24, 48 weeks)
Relapser - a person who has achieved an undetectable level of virus during a prior treatment course of PEG/RBV and relapsed after treatment was stopped
Non-responder - patient who fails to achieve undetectable HCV levels at any point during therapy. Non-responders include both null-responders and partial responders.
  - Null-responders describe patients who experience a minimal viral suppression (serum HCV RNA levels declined less than 2 log10 IU/mL by week 12 during a prior treatment course)
  - Partial responders are patients with a ≥ 2 log10 IU/mL response whose virus remained detectable up to 24 weeks or the end of treatment
Slow-responder - patient who has detectible HCV at weeks 4 and 12, but has undetectable HCV by week 24.
Undetectable (or negative) viral load – viral load is below the limit of detection for the specific test. e.g., a Branched-chain DNA (bDNA) test can only detect viral loads greater than 615 IU/mL.
Detectable (or positive) viral load - the presence of virus is above the limit of detection. This can be expressed as IU/mL, virus/mL, and in logarithmic format.
Aviremic - undetectable HCV RNA on quantitative test (less than 10 IU/mL on Taqman/TMA testing)
Initial Review Criteria – For All Treatment Regimens

Based upon our criteria and assessment of the peer-reviewed literature, Ribavirin, Peg-Intron, Pegasys, Olysio, Viekira, Viekira XR, Sovaldi, Harvoni, ledipasvir/sofosbuvir, Viekira Pak, Daklinza, Technivie, Zepatier, Epclusa, sofosbuvir/velpatasvir, Vosevi, and Mavyret have been medically proven to be effective and therefore **medically necessary** in the treatment of Chronic Hepatitis C if the request meets **ALL** of the following criteria:

1. HCV genotype and quantitative baseline viral load must be provided with a collection date within twelve months before the start of therapy.
   - A. If a patient has received hepatitis c treatment within the past 12 months, recent genotype test results taken after the completion of the previous treatment regimen, will be required to rule out re-infection.

2. The provider must assert to the patient’s treatment readiness and ability to adhere to prescribed treatment regimen.
   - A. At least one scale/assessment tool must have been utilized to evaluate readiness, such as the SAMHSA HRSA Center For Integrated Health Solutions- Drug & Alcohol screen tools (available at [http://www.integration.samhsa.gov/clinical-practice/screening-tools#drugs](http://www.integration.samhsa.gov/clinical-practice/screening-tools#drugs)) OR the Pyschosocial Readiness Evaluation and Preparation for hepatitis C treatment (PREP-C), available at [http://prepc.org/](http://prepc.org/)

3. For Ribavirin-containing regimens, female patients of child bearing potential must have a negative pregnancy test collected within 30 days prior to the initiation of therapy OR Medical records must be submitted documenting pregnancy status.

4. Patients with limited life expectancy (<12 months due to **non-liver related comorbidities**) are not covered.

5. Progress notes are required on all new starts and recertifications.

6. Per IDSA/AASLD guidelines, Victrelis regimens are not recommended for any indication and therefore will only be authorized if there is documentation of a serious adverse reaction or contraindication to the other medications listed in this policy.

7. Patients who are previously cured will not be covered for any treatment upon reinfection **unless the provider attests that risk factors for re-infection have been identified and addressed.**
**Drug Specific Criteria**

<table>
<thead>
<tr>
<th><strong>Mavyret (glecaprevir and pibrentasvir)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Patient must be 12 years or older or weigh at least 45 kg.</td>
</tr>
<tr>
<td>2. Mavyret is not recommended in patients with moderate hepatic impairment (Child-Pugh B) and is contraindicated in patients with severe hepatic impairment (Child-Pugh C), and therefore will not be covered for these patients.</td>
</tr>
<tr>
<td>3. Mavyret is contraindicated with atazanavir or rifampin and therefore will not be covered in patient's taking atazanavir or rifampin.</td>
</tr>
<tr>
<td>4. For <strong>genotype 1,2,3,4,5 or 6</strong> patients, who are <strong>treatment naïve, without cirrhosis</strong>, approval will be <strong>for 8 weeks</strong> for completion of therapy.</td>
</tr>
<tr>
<td>5. For <strong>genotype 1,2,3,4,5 or 6</strong> patients, who are <strong>treatment naïve, with compensated cirrhosis</strong> (Child Pugh A), approval will be <strong>for 12 weeks</strong> for completion of therapy.</td>
</tr>
<tr>
<td>6. For <strong>genotype 1,2,4,5, or 6</strong> patients <strong>without cirrhosis</strong> who are <strong>treatment experienced with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir</strong>, but have no prior treatment experienced with an HCV NS3/4A Protease inhibitor or NS5A inhibitor, approval will be <strong>for 8 weeks</strong> for completion of therapy.</td>
</tr>
<tr>
<td>7. For <strong>genotype 1,2,4,5, or 6</strong> patients, <strong>with compensated cirrhosis</strong> (Child Pugh A), who are <strong>treatment experienced with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir</strong>, but have no prior treatment experienced with an HCV NS3/4A Protease inhibitor or NS5A inhibitor, approval will be <strong>for 12 weeks</strong> for completion of therapy.</td>
</tr>
<tr>
<td>8. For <strong>genotype 3</strong> patients, <strong>without cirrhosis or with compensated cirrhosis</strong> (Child Pugh A), who are <strong>treatment experienced with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir</strong>, but have no prior treatment experienced with an HCV NS3/4A Protease inhibitor or NS5A inhibitor, approval will be <strong>for 16 weeks</strong> for completion of therapy.</td>
</tr>
<tr>
<td>9. For <strong>genotype 1 patients without cirrhosis or with compensated cirrhosis</strong> (Child Pugh A), who have previously failed treatment with a prior regimen containing Harvoni (ledipasvir) or Daklinza (daclatasvir), but have no prior treatment with an HCV NS3/4A Protease inhibitor, the patient must have the same genotype infection on relapse to rule out re-infection. Approval will be for <strong>16 weeks</strong> for completion of therapy.</td>
</tr>
<tr>
<td>10. The following medications are considered NS3/4A protease inhibitor or NS3/4A inhibitor- containing products: Olysio (simeprevir capsules), Victrelis (boceprevir capsules), Incivek (telaprevir tablets), Technivie (ombitasvir/paritaprevir/ritonavir tablets), Viekira Pak (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets, co-packaged), Viekira XR (dasabuvir/ombitasvir/paritaprevir/ritonavir extended-release tablets), Vosevi (sofosbuvir/velpatasvir/voxilaprevir), or Zepatier (elbasvir/grazoprevir tablets).</td>
</tr>
</tbody>
</table>
7. For genotype 1 patients without cirrhosis or with compensated cirrhosis (Child Pugh A), who have previously failed treatment with an HCV NS3/4A Protease inhibitor, but have no prior treatment with an HCV NS5A inhibitor, the patient must have the same genotype infection on relapse to rule out re-infection. Approval will be for 12 weeks for completion of therapy.

- The following medications are considered NS5A inhibitor or NS5A inhibitor-containing products: Harvoni (ledipasvir/sofosbuvir tablets), Epclusa (sofosbuvir/velpatasvir), Zepatier (elbasvir/grazoprevir tablets), Daklinza (daclatasvir tablets), Technivie (ombitasvir/paritaprevir/ritonavir tablets), Viekira Pak (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets, co-packaged), Viekira XR (dasabuvir/ombitasvir/paritaprevir/ritonavir extended-release tablets), or Vosevi (sofosbuvir/velpatasvir/voxilaprevir).

### Harvoni (sofosbuvir/ledipasvir) and authorized generic ledipasvir/sofosbuvir

- **Patient must have genotype 1, 4, 5 or 6** and be 12 years or older or weigh at least 35 kg.
- Harvoni (ledipasvir/sofosbuvir) is not covered in patients with severe renal impairment/ESRD (CrCl <30 mL/min) or hemodialysis-patients.
- Harvoni (ledipasvir/sofosbuvir) is covered as monotherapy or in combination with ribavirin only.
- Please see policy guidelines for definition of cirrhosis.
- Drugs that decrease the gastric PH are expected to decrease concentration of Ledipasvir. Proton-pump inhibitor doses comparable to omeprazole 20mg or lower can be administered simultaneously with Harvoni (ledipasvir/sofosbuvir) under fasted conditions. If H2 receptor antagonists are taken, they should be administered simultaneously with or 12 hours apart from Harvoni (ledipasvir/sofosbuvir) at a dose that does not exceed doses comparable to famotidine 40mg twice daily. It is recommended to separate antacid and Harvoni (ledipasvir/sofosbuvir) administration by 4 hours.
Coadministration of amiodarone with Harvoni(ledipasvir/sofosbuvir) is not recommended due to risk of serious symptomatic bradycardia.

1. For genotype 1 treatment-naïve patients without cirrhosis who have pre-treatment HCV RNA less than 6 million IU/mL, approval will be for 8 weeks for completion of therapy.
   a. For treatment-naive patients who are HIV-HCV co-infected, African American, or who have documentation of a CT or TT type IL28B polymorphism, approval will be for 12 weeks for completion of therapy.

2. For genotype 1 treatment-naïve patients without cirrhosis who have pre-treatment HCV RNA more than 6 million IU/mL, approval will be for 12 weeks for completion of therapy.

3. For genotype 1 treatment-naïve patients with compensated cirrhosis, approval will be for 12 weeks for completion of therapy regardless of baseline HCV RNA values.

4. For genotype 1 treatment-experienced (defined as patients who have failed an interferon based regimen with or without ribavirin) without cirrhosis, approval will be for 12 weeks for completion of therapy regardless of baseline HCV RNA values.

5. For genotype 1 treatment-experienced (defined as patients who have failed an interferon based regimen with or without ribavirin) with compensated cirrhosis, initial approval will be for 12 weeks with ribavirin.
   a. Requests for 24 week monotherapy with Harvoni require documentation of severe intolerance (that prevents completion of therapy) or contraindication to Epclusa/sofosbuvir-velpatasvir and Mavyret. In addition, documentation of severe intolerance or contraindication to ribavirin is required. Please see policy guidelines for definition of those who are considered ribavirin ineligible.

6. For retreatment of genotype 1 patients who previously failed Sovaldi, the patient must have the same genotype infection on relapse to rule out reinfection. Approval will be for 12 weeks with Ribavirin in patients without cirrhosis.

7. For genotype 4, Harvoni(ledipasvir/sofosbuvir) is approved for 12 weeks in treatment naïve or treatment experienced (defined as patients who have failed an interferon based regimen with or without ribavirin) patients, with or without compensated cirrhosis.

8. For genotype 5 or 6, Harvoni(ledipasvir/sofosbuvir) is approved for 12 weeks in treatment naïve or treatment experienced (defined as patients who have failed an interferon based regimen with or without ribavirin) patients, with or without compensated cirrhosis.
10. For **genotype 1 or 4, 5 or 6** patients who have **decompensated cirrhosis (Class B or C)**, who may or may not be candidates for liver transplantation, including those with Hepatocellular carcinoma, treatment is **covered in combination with ribavirin for 12 weeks**. If patient is ribavirin ineligible, approval will be for 24 weeks as monotherapy. Please see policy guidelines for definition of those who are considered ribavirin ineligible.

---

### Epclusa (sofosbuvir/velpatasvir) and authorized generic sofosbuvir/velpatasvir

- Patient must be **18 years or older**

- Coadministration of amiodarone with Epclusa(sofosbuvir/velpatasvir) is not recommended due to risk of serious symptomatic bradycardia.

- Drugs that increase the gastric PH are expected to decrease concentrations of Velpatasvir. Coadministration of omeprazole or other proton-pump inhibitors is not recommended. If H2 receptor antagonists are taken, they should be administered simultaneously with or 12 hours apart from Epclusa(sofosbuvir/velpatasvir) at a dose that does not exceed doses comparable to famotidine 40mg twice daily. It is recommended to separate antacid and Epclusa(sofosbuvir/velpatasvir) administration by 4 hours.

- The safety and efficacy of Epclusa(sofosbuvir/velpatasvir) is not recommended in patients with severe renal impairment/ESRD (CrCl <30 mL/min) or hemodialysis-patients in treatment guidelines and therefore is not covered.

- Coverage of Epclusa(sofosbuvir/velpatasvir) is excluded in patients who have previously received treatment with a NS5A inhibitor.

1. For **genotype 1, 2, 4, 5, or 6 patients without cirrhosis**, or with **compensated cirrhosis** (Child-Pugh A), coverage will be **for 12 weeks**, in patients who are treatment naïve or treatment experienced (defined as patients who have received treatment with peg interferon alfa/ribavirin with or without an HCV protease inhibitor).

2. For **genotype 3 treatment naïve** patients, with or without compensated cirrhosis and for genotype 3 **treatment experienced** (defined as patients who have received treatment with peg interferon alfa/ribavirin with or without an HCV protease inhibitor) patients **without cirrhosis**, coverage will be for 12 weeks.

3. For **genotype 3 treatment experienced** (defined as patients who have received treatment with peg interferon alfa/ribavirin with or without an HCV protease inhibitor) patients with **compensated cirrhosis**, Epclusa will be **covered in combination with ribavirin** for 12 weeks. AASLD guidelines recommend the addition of ribavirin to increase SVR12 rates, unless contraindicated. If a patient is ineligible to receive ribavirin, Epclusa(sofosbuvir/velpatasvir) will be covered alone for 12 weeks.
5. For **genotype 2** patients who are **sofosbuvir and ribavirin experienced**, Eclusa(sofosbuvir/velpatasvir) will be covered in combination with ribavirin for 12 weeks.

**Zepatier (elbasvir and grazoprevir)**

- Patient must have genotype 1 or 4 and must be 18 years or older
  - For genotype 1 patients, the specific subtype (genotype 1a or 1b) must be provided.
- Zepatier will not be covered for patient with moderate or severe hepatic impairment (Child-Pugh B or C).
- Zepatier will not be covered when being prescribed in patients who are on OATP1B1/3 inhibitors, strong CYP3A inducers, or efavirenz.

- The safety and efficacy of Zepatier have not been established in patients awaiting liver transplant or in liver transplant recipients.

1. For **genotype 1a patients**:
   - For **treatment naïve** or **peg-interferon/ribavirin experienced** patients **without** baseline NS5A polymorphisms at amino acid positions 28, 30, 31, or 93, approval will be for 12 weeks of Zepatier monotherapy.
   - For **treatment naïve** or **peg-interferon/ribavirin experienced** patients **WITH** baseline NS5A polymorphisms at amino acid positions 28, 30, 31, or 93, approval will be for 16 weeks in combination with ribavirin.
   - For genotype 1a patients who are Peg-interferon/ribavirin/protease inhibitor experienced, approval will be for 12 weeks of Zepatier in combination with Ribavirin.

2. For **genotype 1b patients** who are **treatment naïve** or **peg-interferon/ribavirin experienced**, approval will be for 12 weeks of Zepatier monotherapy.

3. For **genotype 1b patients** who are **peg-interferon/ribavirin/protease inhibitor experienced**, approval will be for 12 weeks in combination with ribavirin.

4. For **genotype 3, peg interferon/ribavirin treatment experienced** patients, with **compensated cirrhosis**, Zepatier will not be authorized for new starts unless there is documentation of severe intolerance (that prevents completion of therapy) with Eclusa or contraindication to Eclusa. For these patients, approval will be for 12 weeks in combination with Sovaldi.

5. For **genotype 4** patients who are treatment naïve, approval will be for **12 weeks** of Zepatier monotherapy.
6. For genotype 4 patients who experienced virologic relapse after prior Peg-interferon/ribavirin therapy, approval will be for **12 weeks of Zepatier in combination with Ribavirin**. For genotype 4 patients who experienced prior on-treatment virologic failure (failure to suppress or breakthrough) while on peg-interferon/ribavirin, approval will be for **16 weeks of Zepatier in combination with ribavirin**.

7. Zepatier will not be authorized for new starts unless there is documentation of severe intolerance (that prevents completion of therapy) with Harvoni/ledipasvir-sofosbuvir and Mavyret and Epclusa/sofosbuvir-velpatasvir or contraindication to Harvoni/ledipasvir-sofosbuvir and Mavyret and Epclusa/sofosbuvir-velpatasvir.

**Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) and Viekira XR**

- Patient **must have genotype 1** and must be 18 years or older
- Must have compensated liver disease (Child-Pugh A). Moderate to severe hepatic impairment is a contraindication (Child-Pugh B and C).
- Not covered in hemodialysis-patients.
- Drug interactions must be assessed. Strong inducers of CYP3A and CYP2C8; and strong inhibitors of CYP2C8 are contraindicated.
- Must be naïve to Viekira/Viekira XR.
- Viekira/Viekira XR is covered as monotherapy or in combination with ribavirin only.
- For indeterminate or mixed genotype 1, follow the genotype 1A dosing guidelines.
- Please see policy guidelines for definition of cirrhosis.

1. For genotype 1A with or without cirrhosis, approval is for 12 weeks in combination with ribavirin. This includes treatment experienced patients who had a partial response or relapse on prior HCV therapy.
   
   a. **Requests for 24 weeks of treatment are only approved for genotype 1A patients with cirrhosis** who is a null responder to previous HCV therapy. Documentation of null response to HCV therapy is needed.

2. For genotype 1B with/without cirrhosis, approval is for 12 weeks monotherapy

3. For post-liver transplant, patient must have mild fibrosis (Metavir fibrosis score 2 or lower). Approval is for 24 weeks in combination with ribavirin.

4. Viekira pak/Viekira XR will not be authorized for new starts unless there is documentation of severe intolerance (that prevents completion of therapy) with Harvoni/ledipasvir-sofosbuvir and Mavyret and Epclusa/sofosbuvir-velpatasvir or contraindication to Harvoni/ledipasvir-sofosbuvir and Mavyret and Epclusa/sofosbuvir-velpatasvir.
### Sovaldi-Based Regimens

- Patient must be 12 years or older or weigh at least 35 kg.
- Sovaldi will not be authorized as monotherapy.
- The safety and efficacy of Sovaldi is not recommended in patients with severe renal impairment/ESRD (CrCl <30 mL/min) or hemodialysis-patients in treatment guidelines and therefore is not covered.

1. Due to the availability of other equally effective, but more cost-effective FDA approved treatment regimens, Sovaldi will **NOT** be covered for **genotype 1** patients.

2. For **genotypes 2 or 3**, Sovaldi will not be covered unless there is documentation of a severe intolerance (that prevents completion of therapy) or contraindication to Epclusa/sofosbuvir-velpatasvir and Mavyret. For patient patients who have documentation of severe intolerance (that prevents completion of therapy) or contraindication to Epclusa/sofosbuvir-velpatasvir and Mavyret, coverage will be provided as follows:
   
   a. For **genotype 2 and 3** patients who are treatment naïve or Peg-interferon/ribavirin experienced **without cirrhosis**, Sovaldi will be covered in combination with daclatasvir (Daklinza) for 12 weeks.
   
   b. For **genotype 2 patients** who are treatment naïve or peginterferon/ribavirin experienced with **compensated cirrhosis**, Sovaldi will be approved in combination with daclatasvir (Daklinza) for 16 or 24 weeks.
   
   c. For **genotype 3 patients** who are treatment naïve with compensated cirrhosis, Sovaldi will be covered in combination with daclatasvir (Daklinza), with or without ribavirin for 24 weeks.
   
   d. For **genotype 3 patients** who are Peg interferon and ribavirin experienced with compensated cirrhosis, Sovaldi will be covered in combination with daclatasvir (Daklinza) and Ribavirin for 24 weeks.
   
   e. For **genotype 2 patients** who are **Sofosbuvir (Sovaldi) plus ribavirin treatment experienced**, Sovaldi will be approved in combination with daclatasvir (Daklinza) with or without weight-based ribavirin for 24 weeks.

3. For patients with **decompensated cirrhosis**, Sovaldi will not be covered unless there is documentation of a severe intolerance (that prevents completion of therapy) or contraindication to Epclusa/sofosbuvir-velpatasvir.
Daklinza (daclatasvir)/Sovaldi (sofosbuvir) combination

- Must be 18 years of age or older
- Daklinza will not be authorized as monotherapy
- Daklinza is contraindicated in combination with drugs that strongly induce CYP3A and may lead to lower exposure and loss of efficacy. These medications include phenytoin, carbamazepine, rifampin, and St. John’s wort.

1. Due to the availability of other equally effective, but more cost-effective FDA approved treatment regimens, Daklinza will NOT be covered for genotype 1 patients.

2. For genotypes 2 or 3, Daklinza will not be covered unless there is documentation of a severe intolerance (that prevents completion of therapy) or contraindication to Epclusa/sofosbuvir-velpatasvir and Mavyret. For patient patients who have documentation of severe intolerance (that prevents completion of therapy) or contraindication to Epclusa/sofosbuvir-velpatasvir and Mavyret, coverage will be provided as follows:
   a. For genotype 2 and 3 patients who are treatment naïve or Peg-interferon/ribavirin experienced without cirrhosis, Daklinza will be covered in combination with Sofosbuvir (Sovaldi) for 12 weeks.
   b. For genotype 2 patients who are treatment naïve or peginterferon/ribavirin experienced with compensated cirrhosis, Daklinza will be approved in combination with Sofosbuvir (Sovaldi) for 16 or 24 weeks.
   c. For genotype 3 patients who are treatment naïve with compensated cirrhosis, Daklinza will be covered in combination with Sofosbuvir (Sovaldi), with or without ribavirin for 24 weeks.
   d. For genotype 3 patients who are Peg interferon and ribavirin experienced with compensated cirrhosis, Daklinza will be covered in combination with Sofosbuvir (Sovaldi) and Ribavirin for 24 weeks.
   e. For genotype 2 patients who are Sofosbuvir (Sovaldi) plus ribavirin treatment experienced, Daklinza will be approved in combination with sofosbuvir (Sovaldi) with or without weight based ribavirin for 24 weeks.

3. For patients with decompensated cirrhosis, Daklinza will not be covered unless there is documentation of a severe intolerance (that prevents completion of therapy) or contraindication to Epclusa/sofosbuvir-velpatasvir.
### Technivie (ombitasvir, paritaprevir, and ritonavir tablets)

- Must be 18 years of age or older
- Must have compensated liver disease (Child-Pugh A). Moderate to severe hepatic impairment is a contraindication (Child-Pugh B and C).

1. For **Genotype 4** patients, **without cirrhosis or with compensated cirrhosis**, approval will be for **12 weeks in combination with Ribavirin**.

2. Due to higher relapse rates, Technivie will only be authorized as **monotherapy** in **genotype 4** patients who are **treatment Naïve, without cirrhosis AND who are ineligible to receive Ribavirin**. Please see policy guidelines for definition of those who are considered ribavirin ineligible.

3. Technivie will not be authorized for new starts unless there is documentation of severe intolerance (that prevents completion of therapy) with Harvoni/ledipsavir-sofosbuvir and Mavyret and Epclusa/sofosbuvir-velpatasvir or contraindication to Harvoni/ledipasvir-sofosbuvir and Mavyret and Epclusa/sofosbuvir-velpatasvir.

### Vosevi (sofosbuvir/velpatasvir/voxilaprevir)

- Patient must be 18 years or older
- Coadministration of amiodarone with Vosevi is not recommended due to risk of serious symptomatic bradycardia.
- Coadministration of Vosevi with HIV regimens containing atazanavir, lopinavir, tipranavir/ritonavir, and efavirenz is not recommended.
- Drugs that increase the gastric PH are expected to decrease concentrations of Velpatasvir. Antacids should be separated from Vosevi administration by 4 hours. H2 receptor Antagonists may be administered simultaneously with or staggered from Vosevi at a dose that does not exceed doses comparable with famotidine 40mg twice daily. Omeprazole 20mg can be administered with Vosevi. Use with other proton Pump-inhibitors has not been studied.
- The safety and efficacy of Vosevi is not recommended in patients with severe renal impairment/ESRD (CrCl <30 mL/min) or hemodialysis-patients in FDA labeling, and therefore, is not covered.
- Vosevi will not be covered in patients with moderate or severe hepatic impairment (Child-Pugh B or C).

1. For **genotypes 1,2,3,4,5 or 6** patients **without cirrhosis or with compensated cirrhosis**, who have previously failed treatment with an NSSA inhibitor, (daclatasvir, elbasavir, ledipasvir, ombitasvir, or velpatasvir), the patient must have the same genotype infection on relapse to rule out re-infection. Approval will be for **12 weeks for completion of therapy**.

2. For **genotypes 1a or 3** patients **without cirrhosis or with compensated cirrhosis**, who have previously failed treatment with a Sovaldi (Sofosbuvir) containing regimen without an NSSA inhibitor, the patient must have the same genotype on relapse to rule out re-infection. Approval will be for **12 weeks for completion of therapy**.
POLICY GUIDELINES:

1. Prior-authorization is contract dependent.

2. Policy may not be applicable to all contracts. Coverage criteria may differ for select contracts.

3. For contracts where Insurance Law § 4903(c-1), and Public Health Law § 4903(3-a) are applicable, if trial of preferred drugs(s) is the only criterion that is not met for a given condition and one of the following circumstances can be substantiated by the requesting provider, then trial of the preferred drug(s) will not be required.
   - The required prescription drug(s) is (are) contraindicated or will likely cause an adverse reaction or physical or mental harm to the member;
   - The required prescription drug is expected to be ineffective based on the known clinical history and conditions and concurrent drug regimen;
   - The required prescription drug(s) was (were) previously tried while under the current or a previous health plan, or another prescription drug or drugs in the same pharmacologic class or with the same mechanism of action was (were) previously tried and such prescription drug(s) was (were) discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event;
   - The required prescription drug(s) is (are) not in the patient’s best interest because it will likely cause a significant barrier to adherence to or compliance with the plan of care, will likely worsen a comorbid condition, or will likely decrease the ability to achieve or maintain reasonable functional ability in performing daily activities;
   - The individual is stable on the requested prescription drug. The medical profile of the individual (age, disease state, comorbidities), along with the rational for deeming stability as it relates to standard medical practice and evidence-based practice protocols for the disease state will be taken into consideration.
   - The above criteria are not applicable to requests for brand name medications that have an AB rated generic. We can require a trial of an AB-rated generic equivalent prior to providing coverage for the equivalent brand name prescription drug.

4. Cirrhosis as defined as any one of the following:
   a. Liver biopsy showing cirrhosis (e.g., Metavir score = 4 or Ishak score ≥ 5) OR
   b. FibroTest® score of > 0.75 AND an APRI > 2 OR
   c. Nodular liver morphology on abdominal ultrasound or CT scan.

5. In the absence of a definitive diagnosis of presence or absence of cirrhosis by the above criteria, a liver biopsy is required; liver biopsy results will supersede blood test results and be considered definitive.

6. Ineligibility to ribavirin is defined as:
   a. Neutrophils <750 cells/mm3, results within the past month or
   b. Hemoglobin < 10g/dL, results within the past month or
   c. Platelets <50 000 cells/ mm3, results within the past month or
   d. Autoimmune hepatitis or other autoimmune condition known to be exacerbated by Ribavirin
   e. Severe intolerance to past ribavirin therapy

7. Ineligibility to interferon therapy are defined as:
   a. Comorbid autoimmune hepatitis or other autoimmune disorders or
   b. Decompensated hepatic disease or history of preexisting cardiac disease or
Pharmacy Management Drug Policy
Chronic Hepatitis C (Commercial)
c. A baseline neutrophil count below 1500/μL or
d. A baseline platelet count below 90,000/μL or
e. Baseline hemoglobin below 10 g/dL or
f. Major uncontrolled depressive illness **despite pharmacologic treatment**, or
g. **Severe intolerance to past IFN therapy** (such as urticaria, angioedema, broncho constriction, anaphylaxis, Stevens-Johnson syndrome, ophthalmologic disorder, thyroid disorder or refractory diabetes mellitus).

8. No early refills will be allowed without a prior authorization to document necessity.

9. Treatment regimens that are not listed within the policy will be evaluated based on current treatment guidelines for safety and efficacy.
   a. Treatment regimens must be listed as a class IIa or higher recommendation in the AASLD HCV guidance or DrugDex to be considered for coverage.

10. Triple therapy with Olysio is not recommended for any genotype and therefore is not included in the policy.

**UPDATES:**

<table>
<thead>
<tr>
<th>Date</th>
<th>Revision</th>
</tr>
</thead>
<tbody>
<tr>
<td>6/19</td>
<td>Revision</td>
</tr>
<tr>
<td>2/19</td>
<td>Revision</td>
</tr>
<tr>
<td>1/19</td>
<td>P&amp;T Approval &amp; Revision</td>
</tr>
<tr>
<td>10/18</td>
<td>Revision</td>
</tr>
<tr>
<td>8/18</td>
<td>Revision</td>
</tr>
<tr>
<td>4/18</td>
<td>Revision</td>
</tr>
<tr>
<td>9/17</td>
<td>P &amp; T Approval &amp; Revision</td>
</tr>
<tr>
<td>8/17</td>
<td>Revision</td>
</tr>
<tr>
<td>7/17</td>
<td>Revision</td>
</tr>
<tr>
<td>3/17</td>
<td>Revision</td>
</tr>
<tr>
<td>8/16</td>
<td>Revision</td>
</tr>
<tr>
<td>6/16</td>
<td>Revision</td>
</tr>
<tr>
<td>4/16</td>
<td>Revision</td>
</tr>
<tr>
<td>3/16</td>
<td>Revision</td>
</tr>
<tr>
<td>2/16</td>
<td>Revision</td>
</tr>
<tr>
<td>11/15</td>
<td>Revision</td>
</tr>
<tr>
<td>8/15</td>
<td>Revision</td>
</tr>
<tr>
<td>7/15</td>
<td>Revision</td>
</tr>
<tr>
<td>5/15</td>
<td>Revision</td>
</tr>
<tr>
<td>2/15</td>
<td>Revision</td>
</tr>
<tr>
<td>1/15</td>
<td>Revision</td>
</tr>
<tr>
<td>11/14</td>
<td>Revision</td>
</tr>
</tbody>
</table>

**REFERENCES:**
1. Pegasys prescribing information- Hoffmann-Roche, Inc. May 2013
2. Peg-Intron prescribing information - Schering Corporation April 2008
Pharmacy Management Drug Policy
Chronic Hepatitis C (Commercial)

10. Incivek Prescribing Information – Vertex Pharmaceuticals, April 2013
16. www.europeanaidsclinicalsociety.org/
23. www.hep-druginteractions.org/
26. Fujie Xu. Estimating the Number of Patients with Chronic Hepatitis C (HCV) Infection Meeting 'Highest' or 'High' Priority Treatment Criteria in the United States. 65th Annual
Meeting of the American Association for the Study of Liver Diseases.
http://natap.org/2014/AASLD/AASLD_74.htm

27. Ira M. Jacobson. Virologic Response Rates to All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir Regimens Are Similar in Patients With and Without Traditional Negative Predictive Factors in Phase 3 Clinical Trials.
http://www.natap.org/2014/AASLD/AASLD_67.htm


30. Technivie Prescribing Information- AbbVie Inc. Accessed March 6, 2017


